Name: 글로벌 시장 동향
SKU: PH1914
Availability: InStock

보고서 요약(국문)

개요
전 세계 만성 면역 혈소판 감소증(ITP) 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
만성 면역 혈소판 감소증(ITP)은 혈소판 분비 감소로 인해 혈액 응고가 저해되어 발생하는 자가면역성 출혈 질환입니다. 정상 혈소판 수는 혈액 1마이크로리터(µL)당 약 15만~40만 개입니다. 혈소판 수가 10만 개/µL 미만인 경우 면역 혈소판 감소증으로 진단될 수 있습니다.
2023년 영남의학학회지에 따르면, 성인 ITP 환자의 약 2/3가 만성 ITP로 진행되지만, 소아 ITP 환자의 경우 20~25%가 만성 ITP로 지속됩니다. 면역혈소판감소증(ITP)의 연간 발생률은 소아 10만 명당 5명, 성인 10만 명당 2명으로 추정됩니다. 스테로이드제는 부작용이 나타나기 때문에 일반적으로 혈소판 생성을 촉진하는 약물이 처방됩니다.
시장 동향: 성장 요인 및 제약 요인
임상 시험 증가
면역혈소판감소증은 면역글로불린, 스테로이드제, 그리고 혈액 응고에 필요한 충분한 혈소판 생성을 돕는 혈소판 자극제를 사용하여 치료합니다. 성인과 소아의 원발성 면역혈소판감소증 치료를 위한 여러 약물이 임상 시험 단계에 있습니다. 모든 약물은 4상 임상 시험 중이며, 곧 시장에 출시될 것으로 예상됩니다.
예를 들어, 옥타파마(Octapharma)는 만성 면역혈소판감소증을 앓는 소아 환자를 대상으로 PANZYGA의 효능과 안전성을 평가하기 위한 4상 임상 시험을 진행하고 있습니다. 시작일은 2020년 1월 21일이며, 예상 완료일은 2024년 4월입니다.
또한, 소비(Sobi, Inc.)는 만성 면역 혈소판 감소증(ITP) 성인 환자를 대상으로 엘트롬보팍(eltrombopag) 또는 로미플로스팀(romiplostim)에서 아바트롬보팍(avatrombopag)으로 전환했을 때의 안전성과 치료 만족도를 평가하기 위한 4상 임상시험을 진행하고 있습니다. 연구 시작일은 2021년 3월 15일이며, 예상 완료일은 2024년 2월 9일입니다.
치둥 가이톈리 의약품(Qidong Gaitianli Medicines Co., Ltd)은 만성 원발성 면역 혈소판 감소증 소아 환자 치료를 위한 회기황 과립의 임상적 효능 및 안전성을 평가하기 위한 4상 임상시험을 진행하고 있습니다. 연구 시작일은 2017년 11월 16일이며, 예상 완료일은 2024년 3월 8일입니다. 이 밖에도 신약 개발의 발전과 파이프라인 신약의 증가는 향후 시장 성장을 견인할 주요 요인입니다.

스테로이드 약물의 부작용
혈소판 감소증 치료에 사용되는 스테로이드 약물의 부작용으로는 심각한 출혈이 있습니다. 코르티코스테로이드의 부작용은 치료 기간이 길어질수록 심해지기 때문에 관리가 어렵습니다. 백내장, 불면증, 고혈압, 당뇨병 대사 변화 등의 부작용 또한 면역성 혈소판 감소증 치료를 위해 스테로이드 약물을 복용하는 환자에게서 나타날 수 있습니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 만성 면역성 혈소판 감소증 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
혈소판 자극제 부문은 시장 점유율의 약 42.7%를 차지했습니다.
혈소판 자극제는 혈소판 감소증 치료에 효과적이기 때문에 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 코르티코스테로이드와 달리 혈소판 자극제는 부작용이 적으면서 효과가 더 뛰어납니다. 효능과 안전성이 향상된 약물의 출시로 성인 및 소아 혈소판감소증 치료가 개선되었습니다.
2022년 10월, 그리폴스의 타발리스(포스타마티닙)는 난치성 만성 면역 혈소판감소증 치료제로 영국 국립보건임상연구소(NICE)의 권고를 받았습니다.
2023년 4월, 킷세이 제약은 만성 특발성 혈소판감소성 자반증 치료제인 타발리스 100mg 및 150mg 정제를 출시했습니다.
지역별 분석
북미는 2022년 시장 점유율의 약 39.8%를 차지했습니다.
미국 인구에서 혈소판감소증 유병률이 높기 때문에 북미는 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 소아의 경우 연간 발생률은 인구 10만 명당 1~6.4명으로 추정됩니다.

성인의 경우 연간 발생률은 인구 10만 명당 1~6건으로 추정됩니다. 그러나 ITP는 성인에서 만성 질환에 가깝기 때문에 유병률은 인구 10만 명당 약 12건입니다. 성인에서 ITP는 60세 이상에서 가장 흔하게 발생합니다.
혈액학 및 종양학 저널(Journal of Hematology and Oncology)에 따르면, 2023년 연구에서 성인 ITP 환자의 사망률이 감염 및 기타 심혈관 질환으로 인해 일반 인구보다 1.3~2.2배 높은 것으로 나타났습니다.
COVID-19 영향 분석
COVID-19는 공급망 차질로 인해 면역 혈소판 감소증 시장에 영향을 미쳤습니다. COVID-19 치료제 및 백신 개발에 연구 개발의 초점이 맞춰지면서 팬데믹 기간 동안 관련 연구가 중단되었습니다. 전 세계적인 봉쇄 조치로 인해 혈소판 감소증 진단이 늦어졌습니다.

경쟁 환경
만성 면역 혈소판 감소증 시장의 주요 글로벌 기업으로는 AbbVie Inc, Amgen Inc., Pfizer, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Novartis International AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Bristol Myers Squibb Inc, F. Hoffmann-La Roche Ltd 등이 있습니다.
주요 개발 사항
• 2023년 8월, InnoCare Pharma는 2023년 6월 30일 기준 2023년도 중간 실적을 발표했습니다. 이 회사는 원발성 면역 혈소판 감소성 자반증(ITP) 치료를 위한 오렐라브루티닙의 개념 증명(PoC)을 달성했으며, 중국에서 3상 임상 등록 시험을 진행 중입니다.
보고서 구매 이유

• 전 세계 만성 면역 혈소판 감소증(CIT) 시장을 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화하여 시각화하고 주요 상업 자산과 주요 업체를 파악합니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 CIT 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

본 글로벌 CIT 시장 보고서는 약 61개의 표, 59개의 그림, 195페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Chronic Immune Thrombocytopenia Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Chronic Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder that occurs due to decreased platelet secretion, preventing blood clotting. An average platelet count ranges from approximately 150,000 to 400,000 per blood microliter (µL). If the count is lower than 100,000/µL of blood, the person might suffer from immune thrombocytopenia.
According to the Journal of Yeungnam Medical Science, 2023, approximately 2/3 of adult ITP cases lead to chronic ITP, but 20% to 25% of pediatric ITP cases persist to chronic ITP. The annual incidence of immune thrombocytopenia (ITP) is estimated to be five cases per 100,000 children and two points per 100,000 adults. Platelet-stimulating agents are generally prescribed to the patients as steroidal drugs show side effects.
Market Dynamics: Drivers & Restraints
Increasing clinical trials
Immune thrombocytopenia is treated with immunoglobulins, steroidal drugs, and stimulating medicines, which help the body release enough platelets for blood clotting. Several drugs are under clinical trials for the treatment of primary immune thrombocytopenia in adults as well as in children. All the drugs are in phase 4 clinical trials, which are expected to be released soon in the market.
For instance, Octapharma is conducting phase 4 clinical trials to evaluate the efficacy and safety of PANZYGA in pediatric patients with chronic immune thrombocytopenia. The start date is January 21, 2020. The estimated completion date is April 2024.
Furthermore, Sobi, Inc. is conducting phase 4 clinical trials to determine the safety and treatment satisfaction in adults With chronic (immune thrombocytopenia)ITP After switching to avatrombopag from eltrombopag or romiplostim. The study start date is March 15, 2021. The estimated completion date is February 9, 2024.
Qidong Gaitianli Medicines Co., Ltd is conducting phase 4 clinical trials to evaluate the clinical efficacy and safety of Huaiqihuang granule for the treatment of children with chronic primary immune thrombocytopenia. The study start date is November 16, 2017. The estimated completion date is March 8, 2024. Furthermore, increasing advancements in drug discoveries, and increasing pipeline drugs are few factors that drive the market in the forthcoming period.
Side effects of steroidal drugs
Side effects of steroidal drugs in treating thrombocytopenia include severe bleeding. The side effects from corticosteroids are challenging to manage because they grow in severity as the treatment extends for a long time. The possible side effects, such as cataracts, insomnia, hypertension, changes in diabetic metabolism, etc, are also seen in people who consume steroidal drugs to treat immune thrombocytopenia.
For more details on this report – Request for Sample
Segment Analysis
The global chronic immune thrombocytopenia are segmented based on drug class, route of administration, distribution channel, and region.
The Platelet stimulating agents segment accounted for approximately 42.7% of the market share
Platelet-stimulating agents are expected to hold the largest market share due to their efficacy in treating thrombocytopenia. Unlike corticosteroids, platelet-stimulating drugs are more efficient with fewer side effects. The launch of medications with more effectiveness and safety helps in the better treatment of thrombocytopenia in adults and children.
In October 2022, Grifols’ TAVLESSE (fostamatinib) received NICE (National Institute for Health and Care Excellence) recommendation for treating refractory chronic immune thrombocytopenia.
In April 2023, Kissei Pharmaceutical Co., Ltd. launched TAVALISSE tab 100mg and 150mg for chronic idiopathic thrombocytopenic purpura.
Geographical Analysis
North America accounted for approximately 39.8% of the market share in 2022
North America is expected to hold the largest region in the market due to the prevalence of thrombocytopenia in the US population. In children, the annual incidence is estimated to be between 1 and 6.4 cases per 100,000 people.
In adults, the annual incidence is estimated to be between 1 and 6 cases per 100,000 people. However, ITP is more of a chronic disease in adults, so the prevalence is approximately 12 per 100,000 cases. The overall incidence in adults occurs in persons over 60 years old.
According to the Journal of Hematology and Oncology, a 2023 study revealed a 1.3–2.2-fold increase in the mortality rate for adult ITP patients compared to the general population due to infection and other cardiovascular events.
COVID-19 Impact Analysis
COVID-19 impacted the immune thrombocytopenia market due to the disruption in the supply chain. Due to the shift in research and development focus toward developing drugs and vaccines for covid 19, the study was halted during the pandemic period. The lockdown was implemented worldwide, postponing the diagnosis of thrombocytopenia to the later stages.
Competitive Landscape
The major global players in the chronic immune thrombocytopenia market include AbbVie Inc, Amgen Inc., Pfizer, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Novartis International AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Bristol Myers Squibb Inc, F. Hoffmann-La Roche Ltd among others.
Key Developments
• In August 2023, InnoCare Pharma released 2023 interim results as of 30 June 2023. The Company has achieved proof of concept (PoC) of orelabrutinib for the treatment of primary immune thrombocytopenia purpura (ITP) and the Phase III registrational trial is ongoing in China.
Why Purchase the Report?
• To visualize the global chronic immune thrombocytopenia market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic immune thrombocytopenia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global chronic immune thrombocytopenia market report would provide approximately 61 tables, 59 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing clinical trials
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of steroidal drugs
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Disease Statistics
5.5. Regional Analysis
5.6. Regulatory Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Immunoglobulins*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Corticosteroids
7.3.1. Prednisone
7.3.2. Dexamethasone
7.3.3. Others
7.4. Thrombopoietin Receptor Agonists
7.4.1. Romiplostim
7.4.2. Avatrombopag
7.4.3. Others
7.5. Platelet Stimulating Agents
7.5.1. Efgartigimod
7.5.2. Others
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Injectables
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. AbbVie Inc
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Amgen Inc.
12.3. Pfizer, Inc.
12.4. Samsung Bioepis Co., Ltd.
12.5. Sanofi S.A.
12.6. Novartis International AG
12.7. Johnson & Johnson Services, Inc.
12.8. Merck & Co., Inc.
12.9. Bristol Myers Squibb Inc
12.10. F. Hoffmann-La Roche Ltd
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

AbbVie Inc, 4. Key Developments, Amgen Inc., Pfizer, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Novartis International AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Bristol Myers Squibb Inc, F. Hoffmann-La Roche Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Chronic Immune Thrombocytopenia Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 7 Global Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Chronic Immune Thrombocytopenia Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Chronic Immune Thrombocytopenia Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 14 North America Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Chronic Immune Thrombocytopenia Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 18 South America Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Chronic Immune Thrombocytopenia Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 22 Europe Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Chronic Immune Thrombocytopenia Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Chronic Immune Thrombocytopenia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Chronic Immune Thrombocytopenia Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Chronic Immune Thrombocytopenia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 AbbVie Inc: Overview

Table 33 AbbVie Inc: Product Portfolio

Table 34 AbbVie Inc: Key Developments

Table 35 Amgen Inc.: Overview

Table 36 Amgen Inc.: Product Portfolio

Table 37 Amgen Inc.: Key Developments

Table 38 Pfizer, Inc.: Overview

Table 39 Pfizer, Inc.: Product Portfolio

Table 40 Pfizer, Inc.: Key Developments

Table 41 Samsung Bioepis Co., Ltd.: Overview

Table 42 Samsung Bioepis Co., Ltd.: Product Portfolio

Table 43 Samsung Bioepis Co., Ltd.: Key Developments

Table 44 Sanofi S.A.: Overview

Table 45 Sanofi S.A.: Product Portfolio

Table 46 Sanofi S.A.: Key Developments

Table 47 Novartis International AG: Overview

Table 48 Novartis International AG: Product Portfolio

Table 49 Novartis International AG: Key Developments

Table 50 Johnson & Johnson Services, Inc.: Overview

Table 51 Johnson & Johnson Services, Inc.: Product Portfolio

Table 52 Johnson & Johnson Services, Inc.: Key Developments

Table 53 Merck & Co., Inc.: Overview

Table 54 Merck & Co., Inc.: Product Portfolio

Table 55 Merck & Co., Inc.: Key Developments

Table 56 Bristol Myers Squibb Inc: Overview

Table 57 Bristol Myers Squibb Inc: Product Portfolio

Table 58 Bristol Myers Squibb Inc: Key Developments

Table 59 F. Hoffmann-La Roche Ltd: Overview

Table 60 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 61 F. Hoffmann-La Roche Ltd: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 2 Global Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 3 Global Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Chronic Immune Thrombocytopenia Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Chronic Immune Thrombocytopenia Market Y-o-Y Growth, By Drug Class, 2022-2031 (%)

Figure 7 Immunoglobulins Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 8 Corticosteroids Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 9 Thrombopoietin Receptor Agonists Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 10 Platelet Stimulating Agents Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 11 Others Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 12 Global Chronic Immune Thrombocytopenia Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 13 Oral Route of Administration in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 14 Injectables Route of Administration in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 15 Others Route of Administration in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 16 Global Chronic Immune Thrombocytopenia Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 17 Hospital Pharmacies in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 18 Online Pharmacies in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 19 Retail Pharmacies in Global Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 20 Global Chronic Immune Thrombocytopenia Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 21 North America Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 22 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 24 South America Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 25 Middle East and Africa Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 26 North America Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 27 North America Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 28 North America Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 29 North America Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 30 North America Chronic Immune Thrombocytopenia Market Share, By Country, 2022 & 2031 (%)

Figure 31 South America Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 32 South America Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 33 South America Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 34 South America Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 35 South America Chronic Immune Thrombocytopenia Market Share, By Country, 2022 & 2031 (%)

Figure 36 Europe Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 37 Europe Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 38 Europe Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 39 Europe Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 40 Europe Chronic Immune Thrombocytopenia Market Share, By Country, 2022 & 2031 (%)

Figure 41 Asia-Pacific Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 43 Asia-Pacific Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 44 Asia-Pacific Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 45 Asia-Pacific Chronic Immune Thrombocytopenia Market Share, By Country, 2022 & 2031 (%)

Figure 46 Middle East & Africa Chronic Immune Thrombocytopenia Market Value, 2022-2031 (US$ Million)

Figure 47 Middle East & Africa Chronic Immune Thrombocytopenia Market Share, By Drug Class, 2022 & 2031 (%)

Figure 48 Middle East & Africa Chronic Immune Thrombocytopenia Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 49 Middle East & Africa Chronic Immune Thrombocytopenia Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 50 AbbVie Inc: Financials

Figure 51 Amgen Inc.: Financials

Figure 52 Pfizer, Inc.: Financials

Figure 53 Samsung Bioepis Co., Ltd.: Financials

Figure 54 Sanofi S.A.: Financials

Figure 55 Novartis International AG: Financials

Figure 56 Johnson & Johnson Services, Inc.: Financials

Figure 57 Merck & Co., Inc.: Financials

Figure 58 Bristol Myers Squibb Inc: Financials

Figure 59 F. Hoffmann-La Roche Ltd: Financials

세계 만성 면역 혈소판 감소증 시장 – 2023-2030

Global Chronic Immune Thrombocytopenia Market - 2023-2030